Industry News
Biotechnology Industry News
AirNexis Therapeutics is taking…
AirNexis Therapeutics is taking flight with $200 million and a clinical-stage asset from a China pharma that aims to treat lung disease.
Madrigal paid Pfizer $50 million…
Madrigal paid Pfizer $50 million for the rights to a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.
Menlo Ventures has made a $16…
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable.
Roche has got in on the B7-H3…
Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing partner MediLink Therapeutics for an ADC targeting the immune checkpoint protein.
Aktis Oncology exceeded its own…
Aktis Oncology exceeded its own expectations for its IPO in a good omen for those hoping for a more inviting public market this year.
After netting a $361 million…
After netting a $361 million series C funding round in October, 2024 Fierce 15 winner Tubulis has reeled in a big name for its chief medical officer spot in Charles Fuchs, M.D. Fuchs is a
The life sciences world is once…
The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026. Fierce Biotech is here tracking the biggest deals, data drops and industry shifts as
After unsheathing just a few…
After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than Genentech’s Vabysmo for patients with diabetic macular edema (DME) in an early-stage study.
As biotech and pharma investment…
As biotech and pharma investment surges nationwide, Ohio is investing $30 million for training the next generation of biomanufacturing talent.
GSK has committed $50 million in…
GSK has committed $50 million in upfront capital and near-term milestones to secure a license to two cancer research foundation models from Noetik.
Tessera Therapeutics is planning…
Tessera Therapeutics is planning to lay off 90 employees, the Flagship-founded biotech has warned.
Protein degradation biotech…
Protein degradation biotech EpiBiologics has brought in $107 million in a star-studded series B round headed up by Johnson & Johnson's and Google's respective venture arms.
Foresee Pharmaceuticals has sold a…
Foresee Pharmaceuticals has sold a chunk of its clinical-stage pipeline in order to focus on the potential of its prostate cancer med Camcevi.
Immuneering has reported updated…
Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to 64% overall survival at 12 months.
Ventyx has achieved its goal of…
Ventyx has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion.
Parabilis is taking an early lead…
Parabilis is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a push for its potential first-in-class cancer drug.
Attempting to scry the future of…
Attempting to scry the future of the pharmaceutical industry, professional services juggernaut PwC has laid out lofty ambitions for what it believes drugmakers could achieve by 2035—as well as the steps those companies should take
Shortly after securing a…
Shortly after securing a partnership with Sanofi, InduPro is linking up with Eli Lilly in efforts to discover new cancer treatments via a pact that could be worth up to $950 million.
With a $125 million series B…
With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class rare disease drug, DIAG723.
Servier is committing to rare…
Servier is committing to rare neurology for the long term, using focused science and strategic collaborations to bring new options to patients in need